Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Exercise Intensity and Postprandial Effects of Breaking Sedentary Behavior in Overweight Adults

NCT07229963 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-09-24

Condition(s) studied

Cardiovascular Risk MarkersPostprandial MetabolismExercise PhysiologySubstrate Oxidation

Investigational drug(s) / intervention(s)

Aerobic Exercise InterventionSprint Exercise InterventionSedentary Behaviour Intervention

Aerobic Exercise Intervention: In the aerobic exercise condition, participants will perform 2 minutes of moderate-intensity (%50 Wattmax) continuous cycling.

Sprint Exercise Intervention: In the sprint condition, participants will complete a 10-second sprint at %200 Wattmax level, as determined during the preliminary test.

Sedentary Behaviour Intervention: Participants will remain seated for a total duration of 7 hours. During this period, they will be instructed to minimize excessive movement and will only be permitted to rise from the chair for voiding purposes.

Study summary

The purpose of this study is twofold: (1) to determine whether breaking up prolonged sitting with aerobic or sprint cycling breaks reduces postprandial blood glucose, insulin, CRP, and blood pressure, which are established risk markers for cardiometabolic diseases; and (2) to assess substrate oxidation during this period in order to identify which exercise condition promotes the greatest increase in fat oxidation.

Eligibility

Sex
ALL
Min age
30 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria * Being physically inactive (not doing at least 150 minutes/week of structured exercise). * Being sedentary (having a daily sedentary time/day for \>7 hours). * Having a BMI between 25 and 29.9 kg/m2. * Having a history of regular menstrual cycles for female participants. * Having medical examination approval. Exclusion Criteria * Taking any acute or chronic medication or supplement that may affect metabolism. * Having an acute or chronic illness that limits exercise (musculoskeletal problems, cardiovascular disorders, respiratory problems, etc.). * Consuming tobacco products. * Meeting 3 or more of the metabolic syndrome criteria (waist circumference of 102 cm or more in men, 88 cm or more in women, triglyceride level of 150 mg/dL or higher, HDL cholesterol level below 40 mg/dL in men and 50 mg/dL in women, blood pressure of 130/85 mmHg or higher, fasting blood glucose level of 100 mg/dL (5.6 mg/L) or higher).

Primary outcome measure(s)

  • Insulin — 7 hour for each experimental condition
    Postprandial insulin. Net incremental area under the curve and total area under the curve for each 7 h condition will be calculated for insulin.

Trial sites (1)

FacilityCityRegionStatus
Hacettepe Sports Science Faculty, Hacettepe Beytepe Clinic Ankara Beytepe Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07229963 on ClinicalTrials.gov ↗ ← All trials in Turkey